Overview

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Status:
Completed

Trial end date:
2021-06-25

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in adults with chronic hepatitis C virus (HCV) infection and compensated cirrhosis.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Sofosbuvir
Sofosbuvir-velpatasvir drug combination
Velpatasvir